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ABSTRACT
Neuroblastoma (NB) is the most common extracranial solid tumor occurring in childhood. Amplification of
the MYCN oncogene is associated with poor prognosis. Downregulation on NB cells of ligands recognized
by Natural Killer (NK) cell-activating receptors, involved in tumor cell recognition and lysis, may contribute
to tumor progression and relapse. Here, we demonstrate that in human NB cell lines MYCN expression
inversely correlates with that of ligands recognized by NKG2D and DNAM1 activating receptors in human
NB cell lines. In the MYCN-inducible Tet-21/N cell line, downregulation of MYCN resulted in enhanced
expression of the activating ligands MICA, ULBPs and PVR, which rendered tumor cells more susceptible to
recognition and lysis mediated by NK cells. Conversely, a MYCN non-amplified NB cell line transfected with
MYCN showed an opposite behavior compared with control cells. Consistent with these findings, an
inverse correlation was detected between the expression of MYCN and that of ligands for NK-cell-
activating receptors in 12 NB patient specimens both at mRNA and protein levels.
Taken together, these results provide the first demonstration that MYCN acts as an immunosuppressive
oncogene in NB cells that negatively regulates the expression of ligands for NKG2D and DNAM-1 NK-cell-
activating receptors. Our study provides a clue to exploit MYCN expression levels as a biomarker to predict
the efficacy of NK-cell-based immunotherapy in NB patients.
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Introduction
High-risk neuroblastoma (NB) remains a highly challenging
pediatric tumor, since 3-y event-free survival remains lower
than 40% despite intensive, multimodal therapies.1 One well-
established predictor of poor prognosis in NB is MYCN ampli-
fication, found in almost 25% of cases. In healthy conditions,
MYCN is scarcely expressed in differentiated adult tissues,
while playing a key role in several pathways involved in the
maintenance of pluripotency.2
Besides downregulation of MHC class I molecules, render-
ing tumor cells resistant to cytotoxic T lymphocytes,3 an addi-
tional mechanism adopted by NB, allowing tumor to escape
innate antitumor immune responses, is downregulation of
ligands for Natural Killer (NK) cell-activating receptors.
Indeed, this downregulation prevents tumor cell recognition
and killing by NK cells4 and, together with releasing of NKG2D
ligands, has been proposed as a mechanism contributing to the
immune evasion strategy in NB.5 The mechanisms that regulate
the expression of such ligands on cellular targets are only par-
tially defined. ULBP1, ULBP2 and ULBP3 genes are regulated
by c-MYC and p53 transcription factors.6,7 At variance with
the majority of tumors, p53 gene is mutated only in 2% of NB,
especially in relapse.8
On the other hand, a complex network of regulators, includ-
ing MDM2,9,10 inhibits p53 function. Remarkably, both p53 and
MDM2 are direct transcriptional targets of MYCN and are co-
expressed at high levels in MYCN-amplified NB cells.11,12 Of
note, NB patients with MYCN-amplified tumors initially
respond to therapy, but rapidly develop drug resistance and fre-
quently suffer relapses13 with tumor cells characterized by abnor-
malities in p53/MDM2 pathway.8 Indeed, p53 is functionally
suppressed by MDM2 in MYCN-amplified NB cells. By contrast,
MYCN expression inversely correlates with that of c-MYC.14
In this study, we show an inverse correlation between the
expression of MYCN and that of ligands for NK-cell
NKG2D- and DNAM1-activating receptors both in a panel
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of human NB cell lines and in primary tumor samples.
Downregulation of MYCN in NB cell lines resulted in upre-
gulation of the surface expression of ligands for such activat-
ing receptors, thereby rendering tumor cells susceptible to
recognition and lysis by NK cells. Taken together, these find-
ings delineate a novel mechanism of NB-driven immune eva-
sion operated by the MYCN oncogene. These data suggest
that MYCN expression level in NB cells represents a poten-
tial biomarker capable of predicting the susceptibility to
therapeutic efficacy of NK-cell-mediated immunotherapy in
high-risk NB patients.
Results and discussion
The levels of MYCN expression are inversely correlated
with those of ligands for NK-cell-activating receptors
in NB cell lines
NK-cell cytotoxicity is triggered by the interaction of NK-cell-
activating receptors with their specific ligands. In particular,
NKG2D receptor recognizes MICA, MICB, ULBP1, ULBP2/5/
6 and ULBP3 ligands,15 while DNAM1 receptor interacts with
PVR and Nectin-2 ligands.16 In addition, certain activating
killer-immunoglobulin-like receptors (KIRs) interact with
MHC class I molecules17 and TRAIL with TRAIL-R2.18
We asked whether the expression levels of the MYCN onco-
gene correlated with a mechanism of immune escape involving
downregulation of NK-cell-activating receptor ligands on NB
cells. To investigate this possible correlation, we assessed the
protein levels of MYCN by western blotting (Fig. S1A) and the
surface expression of activating ligands by flow cytometry
(Table S1) in a panel of 12 NB cell lines, including 6 MYCN
non-amplified (non-MNA) and 6 MYCN amplified (MNA).
Regression analysis of normalized densitometric values of west-
ern blotting and mean fluorescence intensity values of flow
cytometry analysis revealed a significant inverse correlation
between the expression of MYCN and that of the activating
ligands MICA, MICB, ULBP1, ULBP2/5/6, ULBP3 and PVR. A
trend toward an inverse correlation was also found between
expression of MYCN and that of MHC class I and of Nectin-2.
On the other hand, MYCN expression did not correlate with
that of TRAIL-R2 (Fig. 1).
MYCN expression in NB cells is positively correlated with
that of p5312 and inversely with that of c-MYC,14,19 in agreement
Figure 1. Expression of MYCN inversely correlates with that of ligands for NK-cell-activating receptors in NB cell lines. Scatter plots showing the correlation between
MYCN and the surface expression of activating ligands for NK-cell receptors in 12 NB cell lines. The means of four independent immunoblotting analyses of MYCN expres-
sion in NB cell lines are plotted against the means of 15 independent flow cytometric analyses of surface expression of the indicated activating ligands (see Table S1 for
data); Spearman correlation r and p value are shown for each plot.
e1316439-2 E. BRANDETTI ET AL.
with the finding that both transcription factors are involved in
the induction of ULBP ligands.6,7 The function of p53 protein is
inhibited by the MDM2,10 which is overexpressed in many
human cancers,20 including NB.8 Of note, p53 and MDM2 genes
are both direct transcriptional targets of MYCN in NB.11,12
To assess whether p53 and c-MYC could be involved in the
expression of activating ligands in NB, the status of MYCN, c-
MYC, p53 and MDM2 was evaluated in NB cell lines in terms
of amplification, gain, deletion and protein expression by high-
resolution array CGH analysis and western blotting, respec-
tively (Table 1, Fig. S1). p53 gene was lost in four NB cell lines
tested [SK-N-AS, ACN, SK-N-BE(2)c and LA-N-1, due to a
mutation that has been previously reported],21,22 three of them
[SK-N-AS, ACN and SK-N-BE(2)c] also lost MDM2 gene. c-
MYC gene gain was detected in two NB cells lines (SK-N-AS
and ACN), whereas MYCN gene amplification or gain were
found in five [SK-N-BE(2)c, LA-N-1, LA-N-5, SMS-KCNR,
IMR-32] and two (GICAN, SK-N-SH) NB cell lines, respec-
tively (Table 1). All these genetic aberrations were confirmed at
the protein level, except for SK-N-BE(2)c, which expressed
high levels of mutant p53, due to a previously reported
missense mutation.22 Consistently with previously published
studies,11,12,19 MYCN expression was inversely correlated with
c-MYC expression. In contrast, MYCN expression directly cor-
related with both p53 and MDM2 expression, as evaluated in
p53 wt NB cell lines (SH-EP, GICAN, SH-SY-5Y, SK-N-SH,
LA-N-5, SMS-KCNR, IMR-32 and Tet-21/N) (Fig. S1B). This
indicates that p53 is more functional in non-MNA NB cells,
even if expressed at low levels, than in MNA NB cells in which
it is inhibited by MDM2.
Based on these observations, we hypothesize that the inverse
correlation between the expression of MYCN and that of c-
MYC or the p53 functional status could explain differences in
expression of ULBPs ligands in NB cell lines. Whether MICA,
MICB and PVR, whose expression was inversely correlated
with that of MYCN, share the same mechanism of regulation of
the ULBPs ligands will be matter of future investigation. More-
over, since higher levels of soluble MICA have been reported to
be found in sera of NB patients compared with healthy donors,5
the putative role of MYCN in regulating cell surface expression
of activating ligands by non-transcriptional mechanisms cannot
be excluded and needs further investigation.
Altogether, these data demonstrate that MYCN acts as a
negative regulator of the expression of NK-cell-activating
receptor ligands. Our findings support the hypothesis that the
functional suppression of MYCN may represent a potential
strategy to render NB cells more susceptible to NK-cell-medi-
ated recognition and killing.
The modulation of MYCN expression affects that of
NK-cell-activating receptor ligands and the susceptibility
of NB cells to NK-cell-mediated lysis
To investigate whether modulation of MYCN expression could
affect that of activating ligands, we used the conditionally
MYCN-expressing Tet-21/N cell line that loses MYCN expres-
sion following treatment with doxycycline. Doxycycline treat-
ment caused a drastic downregulation of MYCN expression,
early induction of c-MYC expression (at 8 h) and delayed
reduction of p53 and MDM2 expression (at 24 h) (Fig. 2A). Fol-
lowing 16-h treatment with doxycycline, the expression of
MICA, ULBP2/5/6, ULBP3 and PVR was significantly higher in
Doxy-treated Tet-21/N than in untreated Tet-21/N cells. Upre-
gulation of NK-cell-activating receptor ligands was detected up
to 24 h after doxycycline treatment, with a peak at 16 h
(Fig. 2B), followed by a decrease at 3 d (Fig. S2A, left panel). By
contrast, after 10 d of doxycycline treatment downregulation of
NK-cell-activating receptor ligands was detected (Fig. S2A, right
panel). As reported by other authors,23 doxycycline at the con-
centration of 1 mg/mL, 100-fold higher than the dose used in
this study, enhanced the surface expression of MICA and MICB
in different tumor cell lines. To exclude that doxycycline could
affect the expression of activating ligands in a MYCN-modula-
tion independent manner, SH-EP and LA-N-5 cell lines, which
lack the Tet response element, were treated with 10 ng/mL of
doxycycline. No change was detected in both cell lines after 16
and 24 h of treatment (Fig. S3). Indeed, in Tet-21/N cell line a
state of cell senescence was detected 16 h after doxycycline treat-
ment, as evaluated by cell count at different time points showing
stable cell number due to a block in cell proliferation (data not
shown) and by senescence associated-b-galactosidase (SA-
b-Gal) staining (Fig. S2B, upper panel). Three days after doxy-
cycline treatment, the occurrence of cell differentiation, revealed
by changes of cell morphology, became evident (Fig. S2B, lower
panel). This finding is consistent with results reported by other
authors24 on the expression of activating ligands in senescent
cells, but not in mature and differentiated cells.
To further confirm that MYCN expression affects that of
NK-cell-activating receptor ligands, we transiently transfected a
non-MNA NB cell line as SK-N-SH with piRV-neoSV vector
bearing MYCN cDNA (SK-N-SH-MYCN) or the empty vector
(SK-N-SH-ctrl) as control. The overexpression of MYCN,
peaking at 16 h and gradually decreasing until 72 h, induced
downregulation of c-MYC (from 16 to 72 h) and upregulation
of both p53 (from 16 to 48 h) and MDM2 (from 16 to 24 h), as
revealed by western blotting (Fig. 2C). SK-N-SH-MYCN cells
showed decreased surface expression of activating ligands as
compared with SK-N-SH-ctrl cells, significantly evident 48 h
after transfection (Fig. 2D).
To test whether the increased expression of NK-cell-activat-
ing receptor ligands induced by MYCN modulation could
affect NK-cell-mediated recognition of NB cells, we performed
degranulation and cytotoxicity assays using untreated and
Doxy-treated Tet-21/N cells, as well as SK-N-SH-ctrl and SK-
N-SH-MYCN cell lines as targets. After 16-h treatment with
doxycycline, Tet-21/N cells were significantly more susceptible
to NK-cell-mediated lysis than untreated cells in both degranu-
lation and cytotoxicity assays (Figs. 3A and B). Conversely,
SK-N-SH-MYCN cell lines were less susceptible to NK cell rec-
ognition and lysis, compared with control cells, as evaluated in
both degranulation and cytotoxicity assays (Figs. 3C and D). Of
note, Tet-21/N cells treated with doxycycline for 3 and 10 d
were less susceptible to NK-cell-mediated recognition than
untreated cells (Fig. S2C).
These results revealed that MYCN overexpression contrib-
utes to protect NB cells from NK-cell-mediated recognition
and killing, thus delineating a novel mechanism of tumor
escape from the control of the innate immune system, that is
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Figure 2. Modulation of MYCN affects the expression of ligands for NK-cell-activating receptors. (A) Representative example of immunoblot analysis of MYCN, c-MYC, p53
and MDM2 in Tet-21/N either left untreated (0) or treated with doxycycline for the indicated time (left panel). An anti-Actin Ab was used for normalization. Densitometry
analysis of Actin-normalized proteins values of three independent experiments are shown (right panel). Mean § SD; p < 0.05, p < 0.01. (B) Representative flow cyto-
metric analysis of surface expression of activating ligands for NK-cell receptors in Tet-21/N either left untreated (medium, gray line) or treated with doxycycline for 16 h
(Doxy, red line); dotted lines, isotype-matched negative controls (left panel). Summary of five independent flow cytometric analyses (right panel). p values, compared
with untreated and Doxy-treated Tet-21/N cells (two-tailed paired Student’s t-test); p < 0.05, p < 0.01. (C) Representative example of immunoblot analysis as in A of
SK-N-SH either left transfected with empty vector (ctrl) or with piRVneoSV-MYCN (MYCN) for the indicated time (left panel). Densitometry analysis of Actin-normalized
proteins values of three independent experiments are shown (right panel). Mean § SD; p < 0.05, p < 0.01. (D) Representative flow cytometric analysis of surface
expression of activating ligands for NK-cell receptors in SK-N-SH transfected for 48 h with control vector (ctrl, gray line) or with MYCN cDNA vector (MYCN, blue line); dot-
ted lines, isotype-matched negative controls (left panel). Summary of five independent flow cytometric analyses (right panel). p values, compared with ctrl and MYCN
cDNA vector transfected cells (two-tailed paired Student’s t-test); p < 0.05, p< 0.01.
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mediated by the repression of NK-cell-activating receptor
ligands. This immune evasion mechanism adds to another
already reported in relation to NB-infiltrating NKT cells, that is
mediated by the inhibition of chemokine production.25 These
data suggest that a pharmacologic treatment aimed at decreas-
ing MYCN expression in high-risk NB could represent a novel
valuable therapeutic strategy to restore the NK-cell-mediated
immune response against tumor cells.
The expression of MYCN in primary NB samples is inversely
correlated with that of ligands for NK-cell-activating
receptors
Next, the expression of MYCN and that of MICA, ULBP1,
ULBP2, ULBP3, PVR and Nectin-2 was investigated in 12
different primary NB samples (Table 2) by qPCR. Similarly
to NB cell lines, MYCN expression was inversely correlated
Figure 3. Modulation of MYCN renders NB cells differently susceptible to NK-cell-mediated lysis. (A) Degranulation of human CD3¡CD56C CD45C NK cells from healthy
donors, measured as CD107a cell-surface expression following stimulation with Tet-21/N cells, either left untreated (medium) or treated with doxycycline for 16 h (Doxy).
K562 cells were used as positive control. The percentage of CD107aC NK cells is indicated. A representative experiment out of the eight performed is shown (left panel).
Summary of NK-cell degranulation of cells isolated from eight healthy donors is shown (right panel). Dots, percentage of CD107aC NK cells; horizontal bars, average val-
ues. Dashed lines connect percentage of CD107aC NK cells from each donor cells. p values, compared with untreated and doxycycline-treated Tet-21/N cells (two-tailed
paired Student’s t-test). (B) Tet-21/N untreated or treated as in (A) were tested as targets for NK cells at the indicated effector:target (E:T) ratios in a standard 51Cr-release
assay. One representative experiment out of the five performed is shown (left panel). p values, compared with untreated and doxycycline-treated Tet-21/N cells (two-
tailed paired Student’s t-test); p < 0.05, p < 0.01. Summary of cytotoxic assay of Tet-21/N cells treated as in A and tested as targets of NK cells isolated from five
healthy donors in a standard 51Cr-release assay (right panel). Specific lysis was converted to L.U. 20%. Dots, L.U. 20% of the effector/target pairs tested; horizontal bars,
average values. Dashed lines connect L.U. 20% from each donor cells obtained with the indicated target. p values, compared with untreated and doxycycline-treated Tet-
21/N cells (two-tailed paired Student’s t-test). (C) Degranulation assay of human NK cells, as in (A), following stimulation with SK-N-SH cells transfected for 48 h with piRV-
neoSV vector (ctrl) or with piRVneoSV-MYCN (MYCN). One representative experiment out of the six performed (left panel) and the summary of six experiments (right
panel) are shown. (D) Cytotoxic activity of healthy donor NK cells, as in (B), against SK-N-SH cells transfected for 48 h with ctrl or MYCN cDNA vector. One representative
experiment out of the five performed (left panel) and the summary of five experiments (right panel) are shown.
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with that of activating ligands also in NB patient samples
(Fig. 4A). A significant inverse correlation between the
expression of MYCN and that of MICA and Nectin-2
(Fig. 4B), and a trend toward an inverse correlation between
the expression of MYCN and that of the other activating
ligands (data not shown), was detected. Thus, high levels of
MYCN expression corresponded to low levels of expression
of activating ligands and vice-versa, with the exception for
some activating ligands in patients 6, 12 and 8. Interest-
ingly, primary sample from patient 12 expressed moderate
levels of MYCN and high levels of MICA, ULBP1 and
ULBP2. Notably, this patient had 4S NB, a tumor character-
ized by high rate of spontaneous regression.13
Finally, the expression of MICA and Nectin-2 protein was
evaluated by immunohistochemical assay in primary NB sam-
ples from patient 11 and 3 that displayed markedly different
expression of MYCN mRNA and of activating ligands
(Fig. 4A). The stroma-poor tumor from patient 11, character-
ized by MYCN gain and low differentiation grade (Table 2),
showed low expression of both MICA and Nectin-2 (Fig. 4C,
upper panels). By contrast, the stroma-rich tumor from patient
3, characterized by undetectable MYCN expression, with
mature differentiation grade (Table 2), showed high expression
levels of both MICA and Nectin-2 in ganglion cells (Fig. 4C,
lower panels). Thus, the inverse correlation between the expres-
sion of MYCN and MICA and Nectin-2 ligands, detected at the
mRNA level, was confirmed at the protein level in primary NB
samples.
In conclusion, this study shows that the expression of
MYCN is inversely correlated with that of the activating
ligands for NKG2D and DNAM1 NK-cell receptors in NB
cells. As a consequence, MYCN expression could represent
a biomarker allowing to predict the susceptibility of NB
cells to NK-cell-mediated immunotherapy. In addition, we
suggest that MYCN targeting could represent a novel thera-
peutic strategy to induce the expression of activating ligands
in MNA NB samples. Further investigations exploiting the
potential activation of NK cells against NB cells following
treatment with drugs able to efficiently downmodulate
MYCN levels are warranted.
Materials and methods
Cell lines and reagents
Human NB cell lines were obtained as follow: GICAN and
ACN from Interlab Cell Line Collection, Banca Biologica and
Cell Factory (www.iclc.it), SK-N-AS, SH-SY5Y, SH-EP, SK-N-
SH, SK-N-BE(2)c, IMR-32 from the American Type Culture
Collection (ATCC), LA-N-1 from Creative Bioarray, LA-N-5
from the Leibniz-Institut DMSZ, SMS-KCNR from Children’s
Oncology Group Cell Culture, while the Tet-21/N cell line was
kindly provided by Dr M. Schwab (University of Heidelberg,
Heidelberg, Germany). All NB cell lines were characterized by
(i) HLA class I typing by PCR-SSP sets (Genovision) according
to the manufacturer’s instructions, and (ii) array CGH (see
below). The human erythro-leukemia cell line K562 was pur-
chased from ATCC and used as control target for NK cell func-
tional assays. Cells were grown in RPMI 1640 medium
supplemented with 10% FBS (Thermo Fisher Scientific), 2 mM
glutamine, 100 mg/mL penicillin and 50 mg/mL streptomycin
(Euro Clone S.p.a.). Doxycycline (Sigma Aldrich) was used at
10 ng/mL. Lipofectamine 2000 was used, according to manu-
facturer’s instructions (Invitrogen), to transfect SK-N-SH cells
with pIRVneoSV empty vector or pIRVneoSV-MYCN, both
kindly provided by G. Giannini (“La Sapienza” University of
Rome, Italy).
Patient samples
Tumor samples from 12 NB patients and sections of normal
intestinal mucosa and colon carcinoma, diagnosed at the Bam-
bino Gesu Children’s Hospital, were used. For each patient,
written informed parental consent and approval by the Ethical
Committee of the Institution were obtained. Details on clinical
information are provided in Supplementary Materials and
Methods.
Antibodies, western blotting and flow cytometry
The following antibodies were used: anti-MYCN, anti-p53,
anti-Actin (B8.4.B, FL-393 and I-19, respectively, Santa Cruz
Table 2. Diagnostic characteristics of NB patients.
Patient
number Age Stage Subtypex MYCNb 1qDelg
Diagnostic
categoryd
Differentiation
gradee
Histological
classificationu
Tumor
sideλ Follow-up
1 16y 9m 1 GN un un SD M fav. A alive
2 7y 1 GN un un SD M fav. EA alive
3 3y 4m 3 GN un un SD M fav. EA alive
4 7y 2m 1 GNBL un un SR / / M alive
5 1y 6m 1 NB no no SP SD fav. A alive
6 3m 1 NB no no SP SD fav. A alive
7 8m 1 NB no no SP SD fav. EA alive
8 16y 8m 2 NB no imb. SP SD unf. EA alive
9 1y 8m 4 NB yes imb. SP SD fav. EA dead
10 1y 4m 4 NB gain no SP SD unf. A alive
11 3y 11m 4 NB yes no SP SD unf. EA alive
12 4m 4s NB no no SP SD fav. A alive
xGN: ganglioneuroma; GNBL: ganglioneuroblastoma; NB: neuroblastoma.
b gun: undetectable; no: no-amplified; yes: amplified; imb.: imbalance.
dSD: stroma dominant; SR: stroma reach; SP: stroma poor.
eM: maturing; SD: scarcely differentiated.
ufav.: favorable; unf: unfavorable.
λA: adrenal; EA: extra-adrenal; M: mediastinal mass.
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Biotechnology), anti-MYC (Y69, OriGene), and anti-MDM2
(2A10, Calbiochem-Millipore) for western blotting; anti-
CD107a-FITC (H4A3), anti-CD3-Alexa-700 (UCHT1), anti-
CD56-PE-Cy7 (B159), anti-CD45 (HI30), FITC-conjugated rat
anti-mouse IgG1 (A85–1) and PE-conjugated rat anti-mouse
IgM (R6–60.2) purchased from BD Biosciences; anti-ULBP1-
PE (170818), anti-ULBP2/5/6-PE (165903), anti-ULBP3-PE
(166510), anti-MICA (159227), anti-MICB (236511), anti-
TRAIL/R2-APC (17908), anti-CD155/PVR-PE (300907), anti-
Nectin-2/CD112-APC (610603) purchased from R&D Systems;
W6/32 which recognizes human fully-assembled MHC class I
heavy chains and goat F(ab’)2 Fragment anti-mouse IgG FITC
(IM1619, Dako) for flow cytometry; anti-MICA and anti-
Nectin-2 (62540 and 154895, respectively, Abcam) for immu-
nohistochemistry assay.
Whole-cell extracts were quantified by the bicinchoninic
acid assay (Thermo Fisher Scientific), resolved on 8–10% SDS-
PAGE and electroblotted. Filters were probed with primary
antibodies followed by goat anti-mouse IgG HRP conjugated
(Jackson). Flow cytometry was performed on FACSCantoII
(BD Bioscences) and analyzed by FlowJo Software.
Senescence-associated b-galactosidase (SA b-Gal) activity
Subconfluent Tet-21/N left untreated or treated with doxycy-
cline, cultured in six-well plates, were fixed using 4%
Figure 4. Expression of MYCN and of NK-cell-activating receptor ligands in primary NB cells. (A) qPCR analysis of MYCN and the indicated activating ligands in 12 primary
NB samples. GAPDH was used for normalization. Data were normalized as percentages of the highest value obtained for each marker and plotted as percentage of expres-
sion levels. Data are representative of four experiments. (B) Scatter plots showing the correlation between MYCN and both MICA and Nectin-2 in 12 NB samples. The
means of four independent qPCR analyses, expressed as percentage of expression levels, of MYCN are plotted against those of MICA and Nectin-2; Spearman correlation r
and p value are shown for each plot. (C) Expression of MICA and Nectin-2 in primary NB samples by immunohistochemistry assay. MICA and Nectin-2 expressing cells are
shown in brown. Nuclei are counterstained with hematoxylin (blue). Original magnification, £20. Scale bars 30 mm.
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formaldehyde for 10 min at room temperature, washed twice
with PBS and then stained for b-gal activity at pH 6.0, accord-
ing to manufacturer’s instructions (Promega). Images were
acquired on an Olympus IX51 inverted microscope, and SA
b-Gal positive (blue) cells were counted for five fields of view
(£ 20 magnification) per well.
Array CGH
DNA from NB cell lines was tested by high-resolution array
comparative genomic hybridization (CGH). The test involved
the use of a 180 K platform with a mean resolution of approxi-
mately 40 kb (4 £ 180 platform, Agilent Technologies). A copy
number variant was defined as a displacement of the normal
value of at least three consecutive probes, and the mapping
positions refer to the Genome Assembly hg19 (build 37). The
quality of the test was assessed on the strength of the QCmet-
rics values. Polymorphisms (http://projects.trag.ca/variation/)
were not included because considered normal variants.
Quantitative mRNA expression
Total RNA was extracted using TRIzol Reagent (Thermo Fisher
Scientific). First-strand cDNA was synthesized using the Super-
Script II First Strand cDNA synthesis kit (Thermo Fisher Scien-
tific). Quantitative real-time PCR (qPCR) reactions were
performed using pre-validated TaqMan gene expression assays
from Applied Biosystems, Thermo Fisher Scientific
(Hs00792195_m1 for MICA, Hs00360941_m1 for ULBP1,
Hs00607609_m1 for ULBP2, Hs00225909_m1 for ULBP3,
Hs00197846_m1 for PVR, Hs01071562_m1 for Nectin-2). Rel-
ative gene expression was determined using the 2¡ΔΔCt method
and 2¡ΔCt considered as expression level, with GAPDH
(Hs02758991_g1) as endogenous control.
NK cell isolation
Human NK cells were isolated from peripheral blood mono-
nuclear cells (PBMCs) of healthy donors with the RosetteSep
NK-cell enrichment mixture method (StemCell Technolo-
gies) and Ficoll-Paque Plus (Lympholyte Cedarlane) centri-
fugation. NK cells were routinely checked for the
CD3¡CD56C immunophenotype by flow cytometry and
those with purity greater than 90% were cultured with
600 IU/mL of recombinant human IL-2 (PeproTech) at 37C
and used up to 5 d after isolation.
Cytotoxicity and degranulation assay
NK cell cytotoxic activity was tested by a standard 4-h 51Cr-
release assay. Degranulation assay was performed by co-cultur-
ing NK cells with target cells at 1:1 ratio for 3 h, in complete
medium in presence of anti-CD107a and in the last 2 h of Gol-
giStop (BD Bioscence). Then, cells were stained with anti-
CD56 and anti-CD45 and expression of CD107a was evaluated
by flow cytometry in the CD56CCD45C subset. Specific lysis
was converted to lytic units (L.U.) calculated from the curve of
the percentage lysis. One lytic unit is defined as the number of
NK cells required to produce 20% lysis of 106 target cells during
the 4 h of incubation.
Immunohistochemistry assay
Formaldehyde-fixed paraffin-embedded blocks were cut into 3-
mm sections and baked for 60 min at 56 C in a dehydration
oven. Antigen retrieval and deparaffinization were performed
on a PT-Link (Agilent Technologies) using the EnVision FLEX
Target Retrieval Solution kits at high pH (Agilent Technolo-
gies) for both MICA and Nectin-2, as per manufacturer’s
instruction. Slides were then blocked for endogenous peroxi-
dase for 10 min with a peroxidase blocking solution (Agilent
Technologies), rinsed in the appropriate wash buffer (Agilent
Technologies), and incubated for 30 min with 5% PBS/BSA.
Slides were then incubated overnight at 4C with primary anti-
bodies MICA (1:200) and Nectin-2 (1:300). Twenty minutes
incubation with secondary antibody coupled with peroxidase
(Agilent Technologies) has been subsequently performed.
Bound peroxidase was detected with diaminobenzidine (DAB)
solution and EnVision FLEX Substrate buffer containing perox-
ide (Agilent Technologies). Tissue sections were counterstained
with EnVision FLEX Haematoxylin (Agilent Technologies).
Sections of normal intestinal mucosa and colon carcinoma
were used as positive controls for MICA and Nectin-2, respec-
tively (Fig. S3). Isotype-matched mouse mAbs were used as
negative controls.
Statistical analysis
Digital images of western blotting were analyzed by Image J (http://
rsbweb.nih.gov/ij/index.html) and statistical significance of den-
sitometric values was evaluated by the two-tailed paired Stu-
dent’s t-test. Normalized values were analyzed for correlation
by the regression analysis using GraphPad software. p values
lower than 0.05 were considered to be statistically significant.
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